Upon internalization by tumor cells,the shikonin released from this nanomedicine successfully inhibitedpyruvate kinase isozyme type M2 (PKM2, an essential glycolytic enzyme)and reduced lactate production, ultimately promoting the polarizationof M2-like TAMs toward the M1-like phenotype. This evidence concerns the gene PKM and neoplasm.